Business Wire

XPeng Backed HT Aero Unveils Flying Vehicle City Usage Scenarios

24.9.2021 08:58:00 EEST | Business Wire | Press release

Share

HT Aero, an urban air mobility (UAM) company in which XPeng Inc. is an investor, today unveiled future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 ("X2"), including autonomous flight take-off and landing for specific city scenarios, back-end scheduling, charging and flight control.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923006034/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

XPeng X2 flying vehicle (Photo: Business Wire)

XPeng X2 will present at the 13th Airshow China 2021, starting on September 28 in Zhuhai, Guangdong Province.

X2 is equipped with a robust, highly intelligent flight control system and superior autonomous flying capability, able to conduct autonomous flight route planning, all-round real-time imaging, real-time flight monitoring, two-way real-time communications, all-round environmental perception and autonomous return and landing. It is powered by a highly efficient and convenient charging system, leveraging XPeng’s supercharging technology.

The X2 has an user-friendly interface with one-key start, one-key return, and one-key landing, significantly reducing burdens for the user, delivering a safe and intelligent flight experience.

Before take-off, the system performs intelligent autonomous flight route planning based on the destination entered by the user, comprehensively evaluating factors such as surrounding buildings, no-fly and restricted areas, and weather conditions.

In a graphical recreational video, X2 demonstrates an efficient, effective and environmentally friendly commute from the top apron of a CBD building to a residential building, and connecting to the airport and other transportation hubs, simulating future lifestyle, business travel and other mobility scenarios.

In its first debut at an aerospace exhibition, X2 will be shown on September 28 at the 13th China International Aviation & Aerospace Exhibition (Airshow China 2021), showcasing its cutting-edge design and capabilities.

Introducing XPeng X2, the 5th generation flying vehicle

The XPeng X2 is the latest generation flying vehicle independently developed by HT Aero, having conducted more than 15,000 safe, manned flights. X2 is a pure electric two-seater enclosed-cockpit flying vehicle and an exploration of an aircraft-car integration with significantly improved effective load, passenger number, exterior design and flight control system than the previous generation.

X2 adopts a closed cockpit for the first time, with styling that shares the design language of the XPeng P7. It presents an elegant, minimalist and a teardrop profile. As well as its sci-fi appearance, X2 also takes into account high-efficiency aerodynamics to optimize flight performance.

With a full carbon fiber structure, X2 weighs 560 kilograms (empty aircraft with battery) and has the maximum take-off weight of 760 kilograms with a capacity of two passengers. It can cruise at a maximum design speed of 130 kilometers per hour and has a range of 35 minutes at a designed flying height of under 1,000 meters, suitable for low-altitude urban flight scenarios.

Powered purely by electricity, X2 has no carbon dioxide emissions during flight, in line with the company’s goal of green urban transportation. With 130 kilometers per hour, X2 can meet the needs of short-distance urban transportation, and can serve in scenarios such as air patrol, field rescue, and medical transportation.

About HT Aero

HT Aero aspires to be the leading pioneer of urban air mobility (UAM) and is dedicated to producing safe and intelligent electric flying vehicles which combine automotive and aerospace technologies to realize domestic air-travel usage at scale. Jointly funded and controlled by Mr. He Xiaopeng, XPeng Inc. and ZHAO Deli, HT Aero has a team of highly experienced R&D associates in multiple disciplines such as avionics, test flight, airworthiness, safety, structural mechanics, industrial design and embedded systems. Established in 2013, it has accumulated 15,000 safe, manned flight experiences. For more information, please visit https://www.aeroht.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marie Cheung
mariecheung@xiaopeng.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off

PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release

Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N

AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release

AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To

Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release

Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha

Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye